Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas

Mantle cell lymphoma (MCL) comprises 3–10% of NHL, with survival times ranging from 3 and 5 years. Indolent lymphomas represent approximately 30% of all NHLs with patient survival largely dependent on validated prognostic scores. High response rates are typically achieved in these patients with curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunnellini, Marco, Falchi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384930/
https://www.ncbi.nlm.nih.gov/pubmed/22761620
http://dx.doi.org/10.1155/2012/523842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384930/
https://www.ncbi.nlm.nih.gov/pubmed/22761620
http://dx.doi.org/10.1155/2012/523842

Ejemplares similares